Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions

Respiratory Medicine

Volumn 104, Issue 5, 2010, Pages 682-689

  Abdelrahim, Mohamed E ^a,b  

^a Beni Suef University   (Egypt)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Dose emission; Inhalation twice; Terbutaline sulphate; Turbuhaler; Urine samples

Indexed keywords

BRICANYL TURBUHALER; TERBUTALINE SULFATE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; TERBUTALINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG RESPONSE; DRUG URINE LEVEL; FEMALE; FLOW RATE; HUMAN; INHALATION; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; URINALYSIS; ANALYSIS OF VARIANCE; BIOAVAILABILITY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUBILITY; TREATMENT OUTCOME; URINE;

ADMINISTRATION, INHALATION; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; INHALATION; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUBILITY; TERBUTALINE; TREATMENT OUTCOME;

EID: 77951621404     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.014     Document Type: Article

References (31)

1. Assi K.H., and Chrystyn H. The different resistance of dry powder inhalers (DPIs). Am J Respir Crit Care Med 163 (2001) A443
2. Ross D.L., and Schultz R.K. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med 9 2 (1996) 215-226
3. Newman S.P., Moren F., Trofast E., Talaee N., and Clarke S.W. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 74 2-3 (1991) 209-213
4. Borgstrom L., Bondesson E., Moren F., Trofast E., and Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 7 1 (1994) 69-73
5. Pedersen S., Hansen O.R., and Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 65 3 (1990) 308-310
6. Hawksworth G.M., James L., and Chrystyn H. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir Med 94 5 (2000) 501-504
7. Hindle M., and Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 34 4 (1992) 311-315
8. Abdelrahim M.E., Assi K., and Chrystyn H. Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion: 1. Method Validation [Abstract]. J Aerosol Med 20 2 (2007) P.016
9. United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers, in The United States pharmacopeia 28 [and] The national formulary 23. The Board of Trustees (2005) 2359-2377
10. European Pharmacopeia, 4th Edition, 2.9.18: Preparations for inhalation: aerodynamic assessment of fine particles, Strasbourg, France, 2002. p. 209-217.
11. Pharmacopoeia B. Preparations for inhalation. Aerodynamic assessment of fine particles-fine particle dose and particle size distribution (Ph. Eur. method 2.9.18), in: British Pharmacopoeia (2005), Stationery Office, London A277-290
12. Tarsin W., Assi K.H., and Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 17 1 (2004) 25-32
13. Clark A.R., and Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 6 2 (1993) 99-110
14. Meakin B.J., Cainey J.M., and Woodcock P.M. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulphate from Bricanyl Turbohaler™ dry powder inhalers. Int J Pharm 119 1 (1995) 103-108 (2)
15. Meakin B.J., Cainey J.M., and Woodcock P.M. Drug delivery characteristics of Bricanyl TurbohalerTM dry powder inhalers. Int J Pharm 119 1 (1995) 91-102 (1)
16. Hill L.S., and Slater A.L. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 92 1 (1998) 105-110
17. Prime D., Woodhouse R.N., Grant A.C., and Slater A.L. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 12 2 (1999) 75-84
18. de Boer A.H., Gjaltema D., and Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 138 1 (1996) 45-56
19. Brown P.H., Ning A.C., Greening A.P., McLean A., and Crompton G.K. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 8 11 (1995) 1940-1941
20. Van der Palen J. Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL(R)). Respir Med 97 3 (2003) 285-289
21. Broeders M.E.A.C., Molema J., Hop W.C.J., and Folgering H.T.M. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 16 2 (2003) 131-141
22. Tarsin W., Corrado O.J., Brownlee K., Kanthapillai P., Pearson S., Chetcuti P., and Chrystyn H. Inter-individual variability of peak inhalation rate through different inhalers by asthmatic children and adults and those with COPD. Eur Respir J 18 Suppl. 33 (2001) P900 (133S)
23. Borgstrom L., Derom E., Stahl E., Wahlin-Boll E., and Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 153 5 (1996) 1636-1640
24. Abdelrahim M.E., Assi K., and Chrystyn H. Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a turbuhaler at low inhalation flow. [Abstract]. J Pharm Pharmacol 59 S1 (2007) A39-40 P 105
25. Cazzola M., D'Amato M., Califano C., Di Perna F., Calderaro F., Matera M.G., and D'Amato G. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Therap 24 4 (2002) 595-604
26. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. Eur Respir J 22 6 (2003) 912-919
27. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., and Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
28. Cazzola M., Noschese P., De Michele F., D'Amato G., and Matera M.G. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med 100 2 (2006) 212-217
29. Derom E., Strandgarden K., Schelfhout V., Borgstrom L., and Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 101 9 (2007) 1931-1941
30. ®. Clin Drug Investig 20 1 (2000) 25-33
31. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 97 2 (2003) 181-187